探讨抗CD3单克隆抗体激活的杀伤细胞(anti CD3 monoclonal antibody activated killer cell, CD3AK)对晚期恶性肿瘤的疗效和患者免疫功能的影响。方法: 选取山东大学附属千佛山医院55例实体瘤患者和12例淋巴瘤患者，分离患者外周血单个核细胞，采用抗CD3Ab、IL 2等诱导自体CD3AK细胞，以CD3AK细胞对患者自体回输。并对患者治疗前后的T细胞亚群和NK细胞（CD16 +CD56 +）水平进行测定。 结果: 晚期恶性肿瘤患者输注自体CD3AK细胞1个疗程后,实体瘤组治疗有效率为25.45％，临床获益率为74.54％；淋巴瘤组有效率为83.33％，临床获益率为91.67％；治疗后两组患者T细胞亚群中CD8 + 下降（P<0.05），CD3 +、CD4 +细胞及CD4 +/CD8 +比值及NK细胞计数较治疗前显著升高（P<0.05）。结论：自体CD3AK细胞能使晚期恶性肿瘤患者T细胞亚群比例失调和功能低下的状况得到不同程度的改善，有效地控制肿瘤，而且安全性好,无明显不良反应。

Objective:To investigate the therapeutic effects of anti CD3 monoclonal antibody activated autologous killer cells (CD3AK) in treatment of advanced malignant tumors and their influence on the immune function of patients.Methods: Fifty five patients with solid tumors and 12 with lymphoma, who were admitted to the Qianfoshan Hospital, Shandong University, were treated with CD3AK cells. IL 2 and CD3 Ab were used to induce autologous CD3AK cells from the peripheral blood mono nuclear cells (PBMC) from 67 patients. T cells subsets and the level of NK cells（CD16 +CD56 +）were determined before and after the treatment. Results: The effective rate of autologous CD3AK cells was 2545% for the solid tumors and the clinical beneficial rate was 74.54%; the effective rate was 83.33% for lymphoma and the clinical beneficial rate was 91.67%. The CD8 +cell subsets was decreased after treatment（ P <0.05); the CD3 +，CD4 +cell subsets and CD4 +/CD8 + ratio were significantly increased（ P <0.05）after one course of treatment with CD3AK cells. Conclusion: Autologous CD3AK cells can improve the unbalanced T cell subsets in patients with advanced malignant tumors, upgrade the quality of life of patients, and effectively control tumor growth, with better safety and without adverse effect.

山东省科委自然科学基金资助项目（No.2005ZX04）